Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 15/20 | 0.47 |
| ▸ | F2 | P00734 | 12/20 | 0.47 |
| ▸ | PLG | P00747 | 6/20 | 0.44 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.44 |
| ▸ | PROC | P04070 | 1/20 | 0.44 |
| ▸ | TMPRSS11D | O60235 | 8/20 | 0.43 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.42 |
| ▸ | TMPRSS6 | Q8IU80 | 1/20 | 0.41 |
| ▸ | TMPRSS2 | O15393 | 2/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8289990 | 0.93 | F10 (0.53) | F10F2PLGKLKB1PROC | |
| SCHEMBL8289986 | 0.93 | F10 (0.55) | F10F2PLGKLKB1PROC | |
| SCHEMBL8290737 | 0.93 | F10 (0.53) | F10F2PLGKLKB1PROC | |
| SCHEMBL12156694 | 0.91 | F10 (0.50) | F10F2PLGKLKB1PROC | |
| SCHEMBL8289988 | 0.89 | F10 (0.45) | F10F2PLGKLKB1PROC | |
| SCHEMBL8291002 | 0.89 | F10 (0.56) | F10F2PLGKLKB1PROC | |
| SCHEMBL8291001 | 0.89 | F10 (0.56) | F10F2PLGKLKB1PROC | |
| SCHEMBL8290994 | 0.87 | F10 (0.53) | F10F2PLGKLKB1PROC | |
| SCHEMBL12156728 | 0.86 | ST14 (0.46) | F10F2ST14TMPRSS6PRSS1 | |
| SCHEMBL8289993 | 0.85 | F2 (0.49) | F10F2PLGKLKB1PROC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090658-B2 | Base-substituted benzylamine analogs for use as coagulation factor Xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2015-07-28 | — | — | US | disclosed |
| EP-1664089-B1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | MEDICINES CO LEIPZIG GMBH (DE) | 2011-11-16 | — | — | EP | disclosed |
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | THE MEDICINES COMPANY (LEIPZIG) GMBH (DE) | 2007-03-22 | — | — | US | disclosed |
| WO-2005026198-A1 | BASE-SUBSTITUTED BENZYLAMINE ANALOGS FOR USE AS COAGULATION FACTOR XA INHIBITORS, THE PRODUCTION AND USE THEREOF | CURACYTE CHEMISTRY GMBH (DE) | 2005-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066539-A1 | Base-substituted benzylamine analogs for use as coagulation factor xa inhibitors, the production and use thereof | F12, F2, F11 | F10 6/4885F2 2/4885PLG 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.